MedTrace Logo

Empiric Treatment for Acute HIV in the ED

NCT03711253 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-04-26

No results posted yet for this study

Summary

An acceptance and feasibility study for immediate ART initiation and storage of laboratory specimens for individuals with suspected acute HIV infection who are diagnosed in one of the 7 participating emergency rooms

Conditions

  • Acute HIV Infection

Interventions

DRUG

Bictegravir 50mg+Tenofovir AF 25 mg+emtricitabine 200 mg

antiretroviral therapy

Sponsors & Collaborators

  • University of Southern California

    lead OTHER

Principal Investigators

  • Kathleen Jacobson, MD · University of Southern California

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-14
Primary Completion
2023-06-01
Completion
2023-06-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03711253 on ClinicalTrials.gov